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Sunrnnry and conclusions
Hyperthermic isolated limb perfusion is a major cancer operation, which can have
svstemic ancl local toxic side-effects. Since the introduction of hyperthermic isolated
limb perfusion (HILP), indications for HILP treatment have expanded and new
fields for its applicability are currently being explored. This makes it all the more
important to be continuouslv in-formed about treatment-related toxicity and about
the efficacv of the perfusion therapy with new chemotherapeutic agents anc{
cytokines.
The first part of the introduction reviews the history of the technique of
hl,perthermic isolated limb perfusion, since its introduction in 1958 by Creech and
colleagues. The underlying idea of HILP is to administer high doses of cytotoxic
a€lents locally, with a maximum tumoricidal effect, without giving rise to systemic
sicle-effects. In thc sccond part of the introduction, the tcchnique of HILP is
ciescribccl as well as some technical improvements, developecl to optimize HILP
treatment. The first cytotoxic drug uscd in HILP was the alkvlating agent melphalan
(l--phcnylalanine mustard) and it has been most widely usccl in HILP treatment for
cxtrcmity' malignant melanoma. However HILP treatment for locally advanced
extremity soft-tissue sarcoma (STS) with melphalan did not improve the local control
rate trnd cliscasc-frec survival, when compared to other therapies. Otl-rer drugs used
in HILP, such as cloxorubicin, cisplatin, carboplatin or a cornbination of melphalan
ancl dactinornycin were inferior to melphalan alone in HILP treatment for melanoma
or STS. However, addition of the cytokine tumor necrosis factor-alpha (TNF-a) to
rnelphalan meant a major breakthrough in HILP treatment for locally advanced
cxtrcmity STS. TNF-o attacks tumor vascularization, which results in hemorrhagic
necrosis of the turnor. The beneficial cffcct of adding intcrfcron-gamma (IFN-1) to
HILP with TNF-cr and melphalan is doubtful. The fourth part of the introduction
c'lescribes the role of HILP in rnalignant melanoma treatment. HILP with melphalan
is an established limb-saving treatment modality for local recurrence, in-transit
metastases and satellites of malignant melanoma localized cln the extremities,
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\^,hereas a favorable role ir-r the aeljuvalrt treatment of Stage I melanoma is
questionable. HILP treatment for locally advancecl extremity STS is described in the
fifth part of the inhoduction. It was onlv after the atldition of TNF-a to melphaian
that HILP treatment resulted in high local response rates and high l imb salvage
rates.
Thc research questions which form the basis of this thesis, are formulated at the end
of the introcluction and are dealt with in detaii in the next f ive chapters.
In Chapter II we clescribe a study on functional morbidity in pirt ients treatecl
according to the protocol of the European Orgar-rization for Research ancl 'Ireatment
of Cancer (EORTC). Patients with a high-risk for local recurrence (Stage I extremity
melanoma with n-rore than 1.5 mm Breslow thickness) were prospectively
landomized c)ver a group rvho received HILP treatment with meiphalan followed by
wicle excision (WE, 3 cm margin) or WE alone. The research question was whether
HILP with melphalan adcls to short ancl long-term rnorbiclitv. Morbiclitv was
evaluatecl on the basis of tl-re length of hospitalization, postoperative pain,
postoperative performance and the gracle of perfusion toxicity. At 12-months foilow-
up, a diagnostic physical examination was performed to measure the mobil ity of the
joints as well as the circumference and volume of the treated and untreated
extremities. Eighty-three out of the 97 patients treated accordirrg to the EORTC
protocol at the Groninger-r Universitv }Jospital could be evaluated. Age and sex
distribution were comparablc in the two treatment groups. Forty-six patients
unclerwent HILP+WE and 37 patients underwent WE alone. There was nt'r
treatment-related mortalitV. Treatment-relatecl cornplications were observed in two
patients (1 urine retention and 1 wound dehiscence). For the leg, the period of
hospitalization was an average of 1.9 days longer after HILP+WE, than after WE
alone (p:0.01). This diffcrence was absent for the arm. HILP generated mild local
ioxic reactions (gJrade 2, according to Wieberdink) in the upper extremity, with a
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nlean score of 2.1 (range 2-3) for the lon er extremity. Obviously there were no toxlc
rcactions after WE alone. At 12-months follow-up, the difference in morbidity
Lretween patients after HILP followed bv WE ancl patients after WE alone had
disappearecl. Nevertheless, a number of subjective complaints were encountered in
the HILP+WE group (e.g. pricking sensaticrns or pain during changes in the
weather). However, these complaints did not cause any functional morbidity. This
stuclv showeci that HILP with melphalan clid not cause long-term (functionai)
morbiditv, except for some subjective complaints. A possible explanation for these
cornplaints is fibrosis caused by perfusion. These finclings are in contrast with those
in another publication on this subject which mentioned 25% limitation of motion in
the ankle joint after perfusion. One explanation could be that in Croningen,
fasciotomy was aiwavs performed after HILP to prevcnt a (sub)clinical compartment
syndrome, which may have prevented late fibrosis.
In Chapter III we present a study on angiographic changes in 25 patients treated for
loc.rlly advanced extremity STS with HILP with TNF-a and n-relphalan. TNF-c
targets tumor vascularization by causing selective changes in tumor-associatecl
enclothelial cells, whereas endothelial cells of normal tissue remain unaffected. Aim
of the stucly was to assess whether this effect can be demonstrated arrgiographically
anci whether angiographic changes after HILP with TNF-c, and melphalan wercl
rel.rtecl to the l-ristopathological response clf locally advancecl soft-tissue sarcoma to
HILP treatment.
Angiography was performecl before HILP with TNF-o and melphalan and after a
metiian of 7 (range 4-14) weeks. After a median post-HILP period of eight weeks, the
residual tumor mass was resectecl and examined histopathologically. 'Ihe changes in
tumor vascularization after treatment were scorecl and compared to the
histopathological response. All baseline angiograms showed hypervascularity of the
tumor. After HILP the angiographic findings were normal (NA) in 18 patients (729")
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ancl abnormal (AA) in 7 patients (28%). All the paiients with NA sl-rowed a complete
histopathoic'rgical (pCR) response or tr partial histopathological partial response with
over 90% necrosis of the turnor (pPR>90?;). ln the 7 patients with AA,
histopathologicai exanrination shor.t 'ecl a pCR in 1 pratient, 109; to 50% r' iable tumor
r.olurne in 4 patients antl no histopathological response in 2 p;rtients. Angiographic
arrcl histopathological classification showec{ gooc{ correlation (p<0.il)1). Post-HILP
angiogr.rphy provided an indication of the histopathological response that couid be
expectecl. This may be clf value in cleterming the indication for a second perfusion
treatment.
In Chapter IV the efficacy of acljuvant external bear.n radiotherapr' (EBRT) is
evaluatcd in terms of local disease control, l imb-salvage ancl survival after HILP
trcatmcnt with TNF-a irnd rnelphalan fclr locallv advancec'l extremitv STS. In
adtlition, we addressetl the question of whether EBRT after HILP adds to treatment-
related morbidity.
When HILP with TNF-o and melphalan does not result in cornplete necrosis of a
soit-tissue silrcoma and resection margins are close, external bearn radiotherapy
(EBRT) mav be an adjuvant treatment n-rodality. Tl-ris study clescribes 34 patients
with a locally ach,anced extremity STS, who underwent HILP with TNF-cr ancl
melphalirn. I lesection of the resielual tumor mass was performed in the majority of
patients after 8 weeks. Fifteen patients with histopathological viable tumor after
resection receiveci adjuvant 60-70 Gy EBRT (44%, HILP+EBRT group). Nineteen
patients received HILP without adjuvant EBRT (56%, HILP alone group). Five
patients in the HILP alone group also hacl distant metastases (159i') at the time of
HILP anrl they receivqci HILP with a palliative tretltnlent intent. The limb salvage
r.rte, treatment morbitlity, local recur rence, rcgional and distant metastases \,vere
scored. During a rnediarn follow-up of 34 (range 8-54) months, l imb salvage was
achievecl in 29 patients (85i/"): 14 patients after HILP+EBRT (93%) and 15 patients
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alter HILP alone (79%). None of the patients in the HILP+EBRT group developeci
locai recurrence, whereas 5 patients in the HILP alone group did (26%) (p<0.05).
Regional axillary or inguinal lymph node metastases were observed in 1 patient in
the HILP+EBRT group (7%) and in 2 patients in the HILP alone group (14%). Distant
metastases occurred in 4 patients (27%) after HILP+EBRT and in 4 patients (29%)
after HILP alone with a curative intent. The mean morbidity (SOMA) score in both
groups was 0.33 for skin and subcutaneous tissue. The SOMA scores for muscle and
soft tissue were 0.34 (HILP+EBRT group) ancl 0.33 (HILP alone group) respectively.
The results of this stucly demonstrate that adjuvant EBRT;rfter HILP with TNF-c
ancl rnelphalatt anri delayed tuntor resectiorr of locally advanced extremity STS is
feasible and may increase iocal tumor control without increasing treatment-related
morbiclity.
In Chapter V we present the results of treatment with HILP with TNF-a and
melph;rlan in 15 patients with locirlly advancecl extremity squamous cell carcinoma
or Merkel's cell c.rrcinoma. Lirnb saving is sornetimes impossibie in these patients
using conventional treatment modalities. The encouraging results of HILP treatment
with TNF-a and melphalan in patients with extremity STS raised the question of
i.r'hether this therapv might also be effective in the tretrtment oi other locally
advanced extremitv tumors.
Fifteen pratients witl'r locallv advancecl primar\,, recurrent or metastatic extremity
skin tumors (12 squarnous cell carcinornas, 3 Merkel's cell carcinomas), underwent
HILP rvith TNF-cr and melphalarl as a limb saving therapy. Six tumors were
localizecl in the upper extremity (40%) and 9 in the lower extremity (60?;).
Treatment-relatecl cornplications, lirnb saving rate, local recurrence, regional and
distant metastases were scored during a median follow-up of 20 months. Nine
patients showed a complete response to HILP treatment (60% CR, all
histopatlrcrlogically con{irmetl), 4 patients showed a partial response (27% PR,7
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histttpathologicalh' confimred) arrcl 2 paticrrt showcd no change in the resected
tumor (14% NC-, one histopathologicall l 'confirmed). There were 2 treatment-relateci
cornplications (13?1,). Treatrnent-related mortalitv was 7%.The limb saving rate was
80%, whiie the local recurrcnce rate was 27% (local progression included). Regional
lr ' 'rnph uocle metastascs h/ere observed irr 139/" arrd distantmetastases in 14% of the.
patients treated with a curative intent.
A re'rnarkably high lirnb saving ratc and local control ratc. were achievecl. 'Ihereforc.,
iJILP with TNF-cr ancl rnelphalan should be crlr-rsidered as a l imb saving treatment
rnociality optioll in p;rtients ivith locally arlvanced extremitv srluamous cell c>r
Merkel's cell carcinomer.
lrr Chapter VI the results and cornplications are described of HILP treatment with
TNF-a and mclphalan for locally advancecl extremity STS in 9 patients wl-ro hacl
regional or distant mettrstase's at the timc of HILP. The question was whether HILP
r.r,ith'fNF-a and melphalan is worthwhile rt 'hr'n u-seci with pail iative intent. -fhc
study group comprised 9 patients: 3 had regional and 6 had distant metastases at the
tirnc of thc- initial cliagnosis of a localll' aclvanced extremity STS. One patient haei 2
perfusions, thus 10 pcrfusions were performed. Resectiorr of the residual tumor
mass, if possible, u'as performed 6-8 u'eeks after HILP treatment. Treatment-related
morbiditv, local recurrence and the l imb saving rate were scored. During a rnedian
follon'-up period of 9 (3-39) months, 6 patients dierl from metastatic clisease.
Trcatrnent-relateci morbidity was observed in 3 out oi the 10 perfusions (309'6):
superficial r,vound infection in 2 patients, ancl blow-out of the external i l iac artery
iollowecl bv i l iac thrombosis in 1 ;ratient. Two patients developetl klcai recurrence
aftcr HILP ancl resection, rvhile 1 paticnt sholved local plogression aftcr 2 perfusions
without resection. Limb saving w.rs .rchieved in l l patients (89%). The study results
showcd that HILP with TNF-a and melphalan for localh' arlvanced extremity STS in






I . HILP treatment with melphalan does not
functional morbidity.
cause any additional long-term
IL The response of STS to HILP with TNF-c and melphalan can be demonstrated
with angiography.
Adjuvant EBRT after HILP with TNF-a and melphalan and delayed tumor
resection of locally advanced extremity STS improves locai tumor control,
without increasing treatment-related morbidity.
HILP with TNF-a ancl melphalan has proved to be useful in the treatment of
Iocally aclvanced extremity squamous cell carcinoma and Merkel's cell
carcinoma. HILP with TNF-a and melphalan should be considered as a l imb
saving treatment moclality in patients with advanced extremity tumors that
cannot otherwise be resected curativelv.
V. HILP treatment with TNF-a and melphalan with a paliiative intent can be
worthwhile in patients with regional iymph nocle and distant metastases.
HILP: hyperthermic isolatecl  imb perfusion
WE = wide excision
STS = soft-tissue sarcoma
EBRT = erternal beam ra<iiotherapy
TNF-a - fumor necrosis factor-alpha
IFN-y = interferon-gamma
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